

05-29-01

A
BOXSEA

**NON-PROVISIONAL
UTILITY PATENT APPLICATION
TRANSMITTAL - 37 CFR 1.53(b)**

☐ Duplicate
(check, if applicable)

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Attorney Docket No. 53650-5001
First Named Inventor: Rundell et al.
Express Mail Label No. EL524680672US
Total Pages of Transmittal Form: 2

Transmitted herewith for filing is the non-provisional utility patent application entitled:

**COMPOSITIONS AND METHODS RELATING TO NUCLEIC ACID
REFERENCE STANDARDS**

which is:

an ☒ Original; or

a ☐ Continuation, ☐ Divisional, or ☐ Continuation-in-part (CIP)
of prior Application No. _____.

Anticipated Group/Art Unit: _____ or Class _____, Subclass _____.

☐ This non-provisional patent application is based on Provisional Patent Application
No. _____, filed _____.

Enclosed are:

- ☒ Specification (including Abstract) and claims: 89 pages.
- ☒ Newly unexecuted Declaration (original/copy).
- ☐ Copy of Declaration from prior application.
- ☐ Separate Power of Attorney (including 37 CFR 3.73(b) statement, if applicable).
- ☒ 11 sheets of drawings (formal) plus one copy.
- ☐ Microfiche computer program (Appendix).
- ☒ Nucleotide and/or Amino Acid Sequence Submission, including:
 - ☒ Computer readable copy ☒ Paper Copy (2 pages)
 - ☒ Verified Statement.
- ☐ Under PTO-1595 cover sheet, an assignment of the invention.
- ☐ Certified copy(ies) of _____ Application No(s). _____ filed _____ is/are filed:
 - ☐ herewith or ☐ in prior application _____.
- ☒ Applicants, by their undersigned attorney, claim Small Entity Status under 37
C.F.R. §1.27 as ☐ an Independent Inventor, or ☒ a Small Business Concern, or
☐ a Non-Profit Organization.
- ☐ Preliminary Amendment.
- ☐ Information Disclosure Statement, PTO-1449, and cited references.
- ☐ Other: _____.

The filing fee is calculated as follows:

			SMALL ENTITY			LARGE ENTITY	
CLAIMS	NO. FILED	NO. EXTRA	BASIC FEE:			BASIC FEE:	
			\$355			\$710	
Total	32-20 =	12	X9	\$108.00	OR	X18	\$
Independent	6-3 =	3	X40	\$120.00	OR	X80	\$
<input type="checkbox"/> Multiple Dependent Claims Present			\$135	\$	OR	\$270	\$
			TOTAL	\$583.00	OR	TOTAL	\$

- ☐ The Commissioner is not authorized to charge the filing fee at this time as we elect to defer payment of the entire filing fee until receipt of a Notice to File Missing Parts.
- ☒ A check in the amount of **\$583.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and/or credit **Deposit Account No. 50-0310 (Billing No. 53650-5001)** as noted below. A duplicate copy of this sheet is enclosed.
- ☒ Any overpayments or deficiencies in the above-calculated fee.
- ☐ Filing fee in the amount of \$_____ as calculated above.
- ☒ Any additional fees required under 37 C.F.R. § 1.16 and § 1.17.
- ☐ In the event that a Petition for Extension of Time is required during the prosecution of this application, but not submitted, please charge any extension fee under 37 C.F.R. § 1.136(a) to our Deposit Account noted above.

CORRESPONDENCE ADDRESS:

May 25, 2001
(Date)

By: *Raquel M. Alvarez*
RAQUEL M. ALVAREZ, PH.D., J.D.
 Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, L.L.P.
 1701 Market Street
 Philadelphia, PA 19103-2921
 Telephone: 215-963-5000
Direct Dial: 215-963-5403
 Facsimile: 215-963-5299
 E-Mail: ralvarez@morganlewis.com

☒ Customer Number or Bar Code Label: **028977**

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of RUNDELL <i>et al.</i>	: Group Art Unit: Not Yet Assigned : : :
Appln. No.:	Not Yet Assigned	: Examiner: Not Yet Assigned : :
Filed:	May 25, 2001	: : :
For:	COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID REFERENCE STANDARDS	: Attorney Docket : No. 053650-5001 :

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825**

- (X) I hereby state, in accordance with the requirements of **37 C.F.R. §1.821(f)**, that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with **37 C.F.R. §1.821(c)** and **(e)**, respectively are the same.
- (X) I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(g)** does not include new matter.
- () I hereby state that the submission filed in accordance with **37 C.F.R. §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with **37 C.F.R. §1.825(a)**, included in the substitute sheets of the Sequence Listing are supported in the application, as filed. I hereby state that the substitute sheets(s) of the Sequence Listing does(do) not include new matter.
- () I hereby state that the initial copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(b)**, is the same as the amended Sequence Listing.

- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 C.F.R. §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,

CLARK RUNDELL *et al.*

May 25, 2001
(Date)

By: Raquel M. Alvarez
RAQUEL M. ALVAREZ, Ph.D, J.D.
Registration No. 45,807
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-5403
Facsimile: (877) 432-9652
E-Mail: ralvarez@morganlewis.com
Attorney for Applicants

RMA/GHL

Enclosures: Sequence Listing in Paper and Computer Readable Format

0986633-052501